GlassScriptPhysician profile
Melissa C Chiles
NPI 1205805272
$573.15
in general payments reported to CMS, 2019-2025
14 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.70 · 2023: $97.90 · 2024: $317 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.37 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $84.20 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $70.23 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $66.15 | 2023-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $47.90 | 2024-2025 | Stelara, Tremfya |
| Genentech USA, INC. | $38.75 | 2024-2025 | Xolair |
| Aimmune Therapeutics, INC. | $32.87 | 2025 | Zenpep |
| Genzyme Corporation | $25.80 | 2024 | |
| Acadia Pharmaceuticals INC | $24.42 | 2025 | Daybue |
| Mirum Pharmaceuticals, INC. | $24.27 | 2024 | Livmarli |
| Astellas Pharma US INC | $21.90 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $18.45 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $16.14 | 2024 | Bylvay |
| Hologic Sales and Service, LLC | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.